Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Allergy Immunotherapy Market Growth From $3.55 Billion In 2026 To $5.64 Billion By 2030 At A CAGR Of 12.2%
The global market for allergy immunotherapy has experienced significant expansion lately, with projections indicating continued robust growth from its 2025 valuation of $3.16 billion to a substantial $3.55 billion by 2026, reflecting a compound annual growth rate of 12.3%. This upward trajectory during the preceding period was largely influenced by factors such as a nascent understanding of allergy immunotherapy, an increasing prevalence of seasonal allergic rhinitis, a reliance on healthcare facility treatment pathways, the utilization of established therapeutic approaches, and the successful attainment of regulatory clearances for immunotherapy-based products.
The allergy immunotherapy sector is poised for substantial expansion in the coming years, with projections indicating a market value of $5.64 billion by 2030, driven by a compound annual growth rate of 12.2%. This projected surge is fueled by advancements in tailored immunotherapy approaches, the increasing utilization of digital pharmacies, a broader focus on treating allergies in children, heightened investment in immunotherapy research, and the emergence of combined immunotherapy treatments. Key developments anticipated during this period include a greater embrace of both subcutaneous and sublingual immunotherapy methods, a rise in the incidence of allergic rhinitis and asthma, further development in treating food and insect venom allergies, a more pronounced emphasis on individualized allergy treatment plans, and heightened public awareness coupled with earlier detection of allergic ailments.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9416&type=smp
Allergy Immunotherapy Market Expansion Supported By Key Demand Factors
Fueled by the increasing incidence of allergic conditions, the allergy immunotherapy market is poised for expansion. Allergic disorders are characterized by exaggerated immune system reactions to particular substances. In contrast, autoimmune diseases arise when immune responses mistakenly target the body’s own tissues. Allergy immunotherapy offers a treatment option for individuals with atopic conditions, such as those experiencing IgE-mediated allergic rhinitis and allergic asthma, which are triggered by airborne allergens like pollen and house dust mites. Illustrating this trend, data from August 2023 revealed that in the 2022-23 period, UK hospitals documented over 25,000 admissions for allergies and anaphylaxis, an increase more than double that observed in the preceding two decades, as reported by the Medicines and Healthcare Products Regulatory Agency. Furthermore, the Food Standards Agency’s May 2024 Patterns and Prevalence of Adult Food Allergy (PAFA) report indicated that approximately 6% of UK adults, equating to roughly 2.4 million people, suffer from food allergies. Consequently, the escalating rates of allergic disorders are a primary driver for the growth of the allergy immunotherapy market.
Allergy Immunotherapy Market Segment Analysis: What Are The Major Market Categories?
The allergy immunotherapy market covered in this report is segmented –
1) By Allergy Type: Allergic Rhinitis, Allergic Asthma, Food Allergy, Venom Allergy, Allergic Conjunctivitis, Environmental Allergies
2) By Treatment: Subcutaneous Immunotherapy (SCIT), Sublingual Immunotherapy, Specific Immunotherapy (SIT)
3) By Channel: Hospital Pharmacy, Retail Pharmacy
Subsegments:
1) By Allergic Rhinitis: Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis
2) By Allergic Asthma: House Dust Mite–Induced Allergic Asthma, Pollen-Induced Allergic Asthma, Animal Dander–Induced Allergic Asthma
3) By Food Allergy: Peanut Allergy, Tree Nut Allergy, Milk Allergy, Egg Allergy, Other Food Allergies
4) By Venom Allergy: Bee Venom Allergy, Wasp Venom Allergy, Hornet Venom Allergy, Other Insect Venom Allergies
5) By Allergic Conjunctivitis: Seasonal Allergic Conjunctivitis, Perennial Allergic Conjunctivitis
6) By Environmental Allergies: House Dust Mite Allergy, Pollen Allergy, Mold Allergy, Animal Dander Allergy
Allergy Immunotherapy Market Growth Trends Influencing Competitive Dynamics
Leading players within the allergy immunotherapy sector are actively pursuing product advancements, including the development of artificial intelligence (AI) driven allergy component testing, as a strategy to solidify their market standing. This advanced AI-powered allergy component testing represents a sophisticated diagnostic approach rooted in component-resolved diagnostics (CRD), designed for the accurate identification of diverse allergic conditions. Illustrating this trend, Metropolis Healthcare Limited, a prominent medical laboratory firm based in India, introduced its AI-powered allergy component testing in May of 2023. This cutting-edge, fourth-generation allergy testing technology leverages artificial intelligence to support healthcare professionals in their clinical decision-making processes, offering profound insights that facilitate the selection and refinement of treatment plans for allergic disorders, and moreover, it demonstrates the capability to forecast the potential success of immunotherapy treatments and allergy vaccinations.
Allergy Immunotherapy Market Leading Companies Driving Competitive Growth
Major companies operating in the allergy immunotherapy market are LETI Pharma, Stallergenes Greer International AG, Allergy Therapeutics plc, ALK-Abelló A/S, HAL Allergy B.V., DBV Technologies, Circassia Pharmaceuticals Inc., Jubilant HollisterStier LLC, Allergopharma GmbH & Co. KG, Biomay AG, Anergis SA, HollisterStier Allergy, Desentum Oy, WOLW Pharma Limited, AllerGenics Inc., Greer Laboratories Inc., Aimmune Therapeutics Inc., Reliant Laboratories Inc., Mylan N.V., Adamis Pharmaceuticals Corporation, Endo Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Cipla Ltd.
Access The Complete Allergy Immunotherapy Market Report:
https://www.thebusinessresearchcompany.com/report/allergy-immunotherapy-global-market-report
Allergy Immunotherapy Market Regional Distribution: Which Areas Drive Market Expansion?
Europewas the largest region in the allergy immunotherapy market in 2025. Asia-Pacificis expected to be the fastest-growing region in the allergy immunotherapy market report during the forecast period. The regions covered in the allergy immunotherapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
